FiercePharma21h
JPM25: Bayer gears up for 'must-win battles' as Xarelto's decline is in full swing, pharma chief says
These launches belong to what Oelrich called “must-win battles” at Bayer as Xarelto loss of exclusivity reaches “full swing” ...
Bayer sees new drugs boosting return to growth in 2027, WSJ reports
Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...
Cutting Middle Management: Bayer's Costly Experiment One Year Later
In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.
Bayer says menopause drug succeeds in breast cancer study
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...
Bayer aims to expand presence in India with new therapies and strategic collaborations
Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...
Daily5d
Bayer seeks USFDA nod for Finerenone for adult patients with heart failure
Berlin: Bayer has announced the submission of marketing authorization applications to the U.S. Food and Drug Administration ...
Bayer Aktiengesellschaft (ETR:BAYN) Shares Up 0.4% – Here’s Why
Bayer Aktiengesellschaft (ETR:BAYN – Get Free Report) shares were up 0.4% on Wednesday . The stock traded as high as €19.99 ($20.61) and last traded at €19.79 ($20.40). Approximately 3,072,022 shares ...
Bayer’s Head of Pharma Oelrich Expects Business to Return to Growth in 2027
Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...
Daily8d
Bayer partner seeks approval for Darolutamide plus androgen deprivation therapy for metastatic hormone sensitive prostate cancer
Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...